Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03469999 · ClinicalTrials.gov registry record · Phase 3
Effect of Dysport Injections on Energy Expenditure and Walking Efficiency in Children With Cerebral Palsy
A Phase 3 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
NCT03469999 is a Phase 3 study that has completed, run by Columbia University. The registered enrollment target is 12 participants.
The verdict
NCT03469999, a Phase 3 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study aims to evaluate the efficacy of single event multi level chemoneurolysis with the abobotulinumtoxin A drug, Dysport®, on walking energy expenditure and gait in children with spastic diplegia cerebral palsy.
Interventions
- DRUG Dysport Injectable Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-12-12 |
| Est. Completion | 2021-05-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03469999
The ClinicalTrials.gov registry entry for NCT03469999 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dysport Injectable Product is the first listed.
NCT03469999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03469999 about?
NCT03469999 is a clinical study titled "Effect of Dysport Injections on Energy Expenditure and Walking Efficiency in Children With Cerebral Palsy". This study aims to evaluate the efficacy of single event multi level chemoneurolysis with the abobotulinumtoxin A drug, Dysport®, on walking energy expenditure and gait in children with spastic diplegia cerebral palsy.
What is the current status of trial NCT03469999?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2018-12-12. Estimated completion is 2021-05-26.
What interventions are being tested in trial NCT03469999?
The interventions under investigation include: Dysport Injectable Product (DRUG).
Who is sponsoring clinical trial NCT03469999?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.